Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Support for biologics manufacturability and Industry 4.0 initiatives
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
The plant is scheduled to come on stream in September 2024
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
Subscribe To Our Newsletter & Stay Updated
